Table 3 Tumor characteristics.

Histology - n (%)

0.2677^A

Adenocarcinoma

249 (84.7)

192 (88.1)

441 (86.1)

Mucoid adenocarcinoma

42 (14.3)

23 (10.6)

65 (12.7)

Ring cell carcinoma

1 (0.3)

2 (0.9)

3 (0.6)

Medullary carcinoma

2 (0.7)

0 (0.0)

2 (0.4)

Other

0 (0.0)

1 (0.5)

1 (0.2)

Histology categorization - n (%)

0.4324^A

Adenocarcinoma

249 (84.7)

192 (88.1)

441 (86.1)

Mucoid adenocarcinoma

42 (14.3)

23 (10.6)

65 (12.7)

Other

3 (1.0)

3 (1.4)

6 (1.2)

T stage - n (%)

0.9437

Tx

1 (0.3)

0 (0.0)

1 (0.2)

T1

6 (2.0)

6 (2.8)

12 (2.3)

T2a

8 (2.7)

7 (3.2)

15 (2.9)

T2b

9 (3.1)

7 (3.2)

16 (3.1)

T3

221 (75.2)

164 (75.2)

385 (75.2)

T4

49 (16.7)

34 (15.6)

83 (16.2)

N stage - n (%)

0.3398

N0

100 (34.0)

85 (39.0)

185 (36.1)

N1

137 (46.6)

100 (45.9)

237 (46.3)

N2

57 (19.4)

33 (15.1)

90 (17.6)

Clinical stage - n (%)

0.2464

II

100 (34.0)

85 (39.0)

185 (36.1)

III

194 (66.0)

133 (61.0)

327 (63.9)

Clinical stage subgrups - n (%)

0.2734

II

100 (34.0)

85 (39.0)

185 (36.1)

III low risk

121 (41.2)

91 (41.7)

212 (41.4)

III high risk

73 (24.8)

42 (19.3)

115 (22.5)

Grade - n (%)

0.3639^A

GX

1 (0.3)

3 (1.4)

4 (0.8)

G1

25 (8.6)

13 (6.0)

38 (7.5)

G2

172 (59.1)

135 (62.5)

307 (60.6)

G3

93 (32.0)

65 (30.1)

158 (31.2)

Missing

3

2

5

Chemotherapy taken during the TOSCA trial - n (%)

0.6404

Folfox-4 (6 months)

100 (34.0)

86 (39.4)

186 (36.3)

Xelox (24 weeks)

43 (14.6)

28 (12.8)

71 (13.9)

Folfox-4 (3 months)

110 (37.4)

77 (35.3)

187 (36.5)

Xelox (12 weeks)

41 (13.9)

27 (12.4)

68 (13.3)